Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$1.60 USD
-0.70 (-30.43%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $1.53 -0.07 (-4.38%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Cyclacel Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -22.56 | -21.20 | -18.89 | -8.45 | -7.83 |
Depreciation/Amortization & Depletion | 0.03 | 0.03 | 0.04 | 0.02 | 0.02 |
Net Change from Assets/Liabilities | 4.94 | -1.17 | -0.85 | 0.06 | -2.07 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.47 | 1.51 | 1.16 | 0.43 | 0.43 |
Net Cash From Operating Activities | -16.11 | -20.83 | -18.54 | -7.93 | -9.45 |
Property & Equipment | -0.01 | -0.01 | -0.03 | -0.10 | 0.03 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.01 | -0.01 | -0.03 | -0.10 | 0.03 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.05 | 3.20 | 21.94 | 29.71 | 4.05 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | -0.20 | -0.20 | -0.20 | -0.20 | -0.20 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.85 | 3.00 | 21.74 | 29.50 | 3.85 |
Effect of Exchange Rate Changes | 0.30 | -0.38 | -0.02 | 0.05 | -0.05 |
Net Change In Cash & Equivalents | -14.97 | -18.21 | 3.15 | 21.52 | -5.62 |
Cash at Beginning of Period | 18.35 | 36.56 | 33.41 | 11.89 | 17.50 |
Cash at End of Period | 3.38 | 18.35 | 36.56 | 33.41 | 11.89 |
Diluted Net EPS | -26.75 | -28.49 | -32.08 | -51.27 | -146.93 |
Fiscal Year End for Cyclacel Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -22.56 | -17.28 | -11.25 | -5.80 |
Depreciation/Amortization & Depletion | NA | 0.03 | 0.02 | 0.02 | 0.01 |
Net Change from Assets/Liabilities | NA | 4.94 | 3.91 | 2.31 | -1.47 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 1.47 | 1.15 | 0.76 | 0.40 |
Net Cash From Operating Activities | NA | -16.11 | -12.20 | -8.17 | -6.86 |
Property & Equipment | NA | -0.01 | -0.01 | -0.01 | -0.01 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.01 | -0.01 | -0.01 | -0.01 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 1.05 | 0.00 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | -0.20 | -0.15 | -0.10 | -0.05 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 0.85 | -0.15 | -0.10 | -0.05 |
Effect of Exchange Rate Changes | NA | 0.30 | -0.04 | 0.09 | 0.01 |
Net Change In Cash & Equivalents | NA | -14.97 | -12.40 | -8.18 | -6.91 |
Cash at Beginning of Period | NA | 18.35 | 18.35 | 18.35 | 18.35 |
Cash at End of Period | NA | 3.38 | 5.94 | 10.16 | 11.44 |
Diluted Net EPS | NA | -5.91 | -7.20 | -6.60 | -7.05 |